New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2014
08:07 EDTGALTGalectin Therapeutics secures GR-MD-02 U.S. patent
Galectin Therapeutics announced that the U.S. Patent and Trademark Office issued patent number 8,658,787 to the company for its application titled "Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease." The patent covers the company's carbohydrate-based galectin inhibitor compound GR-MD-02 for use in patients with fatty liver disease with or without fibrosis or cirrhosis, providing patent protection through 2031. Galectin Therapeutics is currently conducting a Phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics and exploratory biomarkers for efficacy for single and multiple doses of GR-MD-02 over four weekly doses of GR-MD-02 treatment in patients with fatty liver disease with advanced fibrosis. Last month, the company announced that patient enrollment in the first cohort of the Phase 1 trial was complete and results are expected to be announced around the end of 1Q14.
News For GALT From The Last 14 Days
Check below for free stories on GALT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for GALT

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use